Bristol Myers' Cancer Drug Doubles Survival: What It Means for BMY

Bristol Myers Squibb announced positive results from a Phase 3 trial of izalontamab brengitecan (iza-bren) in patients with non-small cell lung cancer (NSCLC) who had previously been treated with an EGFR tyrosine kinase inhibitor. The drug doubled progression-free survival (PFS) compared to platinum-based chemotherapy, with median PFS of 11.1 months versus 5.7 months. The safety profile was manageable and consistent with earlier testing.

The trial was conducted in mainland China by Sichuan Biokin Pharmaceutical and its subsidiary SystImmune, which originally developed the drug. Bristol Myers Squibb licensed exclusive rights outside mainland China and the U.S. in December 2023, paying $800 million upfront and committing up to $7.1 billion in milestone payments. The two companies share U.S. rights.

This is the fifth solid tumor type where iza-bren has shown efficacy, according to the company. Bristol Myers' chief medical officer called the results 'highly encouraging' and highlighted the drug's potential to address unmet needs in oncology.

Despite the strong data, BMY stock inched up only marginally on Monday. The muted reaction reflects investor caution about the drug's path to approval in major markets like the U.S. and Europe.

The main reason for the tepid response is that the trial was conducted solely in China. The FDA typically requires multi-region data that meet Western standards of care before approving a drug, so U.S. approval is likely years away. This limits the near-term commercial opportunity for Bristol Myers.

Additionally, overall survival (OS) data were immature. OS is considered the gold standard in cancer trials, and without mature OS data, it's unclear whether the PFS benefit will translate into longer lives. Subsequent therapies can also dilute PFS gains.

Bristol Myers is still heavily dependent on legacy drugs that have lost or are losing patent protection. Even a blockbuster new drug would take time to offset those losses. The company is actively building its growth portfolio, but iza-bren is just one piece of the puzzle.

Competition is another factor. Johnson & Johnson and other companies are developing similar drugs targeting solid tumors. If competitors bring their products to market first or with better data, iza-bren's commercial potential could be squeezed.

For investors, the news is a positive signal about Bristol Myers' R&D strategy and pipeline, but it doesn't change the near-term earnings outlook. The stock's muted reaction reflects that reality.